@article{3145582,
    title = "Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from
the EPIC cohort, plus a meta-analysis of prospective studies",
    author = "Rinaldi, Sabina and Cleveland, Rebecca and Norat, Teresa and Biessy, and Carine and Rohrmann, Sabine and Linseisen, Jakob and Boeing, Heiner and and Pischon, Tobias and Panico, Salvatore and Agnoli, Claudia and Palli, and Domenico and Tumino, Rosario and Vineis, Paolo and Peeters, Petra H. M. and and van Gils, Carla H. and Bueno-de-Mesquita, Bas H. and Vrieling, Alina and and Allen, Naomi E. and Roddam, Andrew and Bingham, Sheila and Khaw, and Kay-Tee and Manjer, Jonas and Borgquist, Signe and Dumeaux, Vanessa and and Gram, Inger Torhild and Lund, Eiliv and Trichopoulou, Antonia and and Makrygiannis, Georgios and Benetou, Vassiliki and Molina, Esther and and Donate Suarez, Ignacio and Barricarte Gurrea, Aurelio and Gonzalez, and Carlos A. and Tormo, Maria-Jose and Altzibar, Jone M. and Olsen, Anja and and Tjonneland, Anne and Gronbaek, Henning and Overvad, Kim and and Clavel-Chapelon, Francoise and Boutron-Ruault, Marie-Christine and and Morois, Sophie and Slimani, Nadia and Boffetta, Paolo and Jenab, Mazda and and Riboli, Elio and Kaaks, Rudolf",
    journal = "International Journal  of Cancer",
    year = "2010",
    volume = "126",
    number = "7",
    pages = "1702-1715",
    publisher = "Wiley-Blackwell",
    issn = "0020-7136",
    doi = "10.1002/ijc.24927",
    keywords = "insulin-like growth factor-I (IGF-I); colorectal neoplasms; nested case
control study; European Prospective Investigation into Cancer (EPIC);
meta-analysis",
    abstract = "Several prospective studies have shown a moderate positive association
between increasing circulating insulin-like growth factor-I (IGF-I)
levels and colorectal cancer risk. However, the associations were often
statistically nonsignificant, and the relationship of cancer risk with
IGF-I’s major binding protein, IGFBP-3, showed major discrepancies
between studies. We investigated the association of colorectal cancer
risk with serum IGF-I, total and intact IGFBP-3, in a case-control study
nested within the EPIC cohort (1,121 cases of colorectal cancer and
1,121 matched controls). Conditional logistic regression was used to
adjust for possible confounders. Our present study results were combined
in a meta-analysis with those from 9 previous prospective studies to
examine the overall evidence for a relationship of prediagnostic serum
IGF-I with colorectal cancer risk. In the EPIC study, serum
concentrations of IGF-I and IGFBP-3 showed no associations with risk of
colorectal cancer overall. Only in subgroup analyses did our study show
moderate positive associations of IGF-I levels with risk, either among
younger participants only (and only for colon cancer) or among
participants whose milk intakes were in the lowest tertile of the
population distribution (RR for an increase of 100 ng/ml = 1.43 [95%
CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive
association remained between serum IGF-I and colorectal cancer risk
overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in
IGF-I). Overall, data from our present study and previous prospective
studies combined indicate a relatively modest association of colorectal
cancer risk with serum IGF-I."
}